Pancuronium Bromide Injection Rx
Generic Name and Formulations:
Pancuronium bromide 1mg/mL, 2mg/mL; soln for IV inj; contains benzyl alcohol.
Various generic manufacturers
Indications for Pancuronium Bromide Injection:
Adjunct to general anesthesia to facilitate tracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation.
Adults and Children:
Individualize. Adjunct to anesthesia: Initially 0.04 to 0.1mg/kg, then may use incremental doses starting at 0.01mg/kg. Relaxation for intubation: inject bolus dose of 0.06 to 0.1mg/kg. Neonates: give test dose 1st of 0.02mg/kg. Monitor with a peripheral nerve stimulator to avoid overdosage.
To be administered under the supervision of experienced clinicians. Have intubation, artificial respiration, oxygen therapy and reversal agents available. Myasthenia gravis or myasthenic (Eaton-Lambert) syndrome (do test dose and monitor). Pre-existing pulmonary disease. Renal disease or failure. Hepatic and/or biliary tract disease. Cardiovascular disease and edematous state. Long-term use in I.C.U. Immobilized for long periods. Severe obesity or neuromuscular disease; monitor airway and ventilation. Electrolyte imbalance. Adrenal cortical insufficiency. Neonates. Elderly. Pregnancy (Cat.C). Nursing mothers.
Prior administration of succinylcholine may potentiate effects (delay dose or give pancuronium 1st). Potentiated by volatile inhalational anesthetics (eg, enflurane, isoflurane, halothane), aminoglycosides, tetracyclines, bacitracin, polymyxin B, colistin, sodium colistimethate, magnesium salts. Significant additive effects with pancuronium bromide-metocurine and pancuronium bromide-d-tubocurarine combinations than with the individual drugs given alone. Potential severe ventricular arrhythmias in concomitant with tricyclics and halothane. Caution with quinidine injection.
Neuromuscular blocker (nondepolarizing).
Skeletal muscle weakness or prolonged paralysis, circulatory effects, salivation, transient rash; rare: hypersensitivity reactions.
Formerly known under the brand name Pavulon.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Risk for Cardiovascular Disease Higher in Survivors of Testicular Cancer
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|